Immuron IMRN
NASDAQ IMRN
$1.77 -0.07 (-3.80%)
As of: Sep 9, 2026 · 3:59 PM EDT

Immuron (IMRN) Income towards Parent Company (2016 - 2025)

Immuron (IMRN) posted Income towards Parent Company of -$3.3 million for Q2 2025, down 7126.84% on a QoQ basis from -$46223.4 in Q3 2024, and up 26.93% year-over-year from -$2.6 million in Q2 2024.

Analysis

Immuron (IMRN) Income towards Parent Company (2016 - 2025) Analysis & Trends

Immuron has reported Income towards Parent Company for 10 years, with the latest figure at -$3.3 million in Q2 2025.

  • On a quarterly basis, Income towards Parent Company rose 26.93% year-over-year to -$3.3 million in Q2 2025; TTM through Jun 2025 was -$8.0 million, a 29.02% decrease from a year earlier, with the FY2026 full-year figure at -$3.8 million, down 7207.34% from the prior year.
  • Income towards Parent Company was -$3.3 million for Q2 2025 at Immuron, down from -$46223.4 in the prior quarter.
  • The five-year high for Income towards Parent Company was -$13260.2 in Q4 2021, with the low at -$6.5 million in Q2 2021.
  • Average Income towards Parent Company over 5 years is -$2.0 million, with a median of -$795595.5 recorded in 2022.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company slumped 2558.11% in 2022, then jumped 93.01% in 2023.
  • Over 5 years, Income towards Parent Company stood at -$13260.2 in 2021, then plunged by 2558.11% to -$352470.5 in 2022, then surged by 93.01% to -$24649.8 in 2023, then tumbled by 87.52% to -$46223.4 in 2024, then plunged by 7126.84% to -$3.3 million in 2025.
  • The last three Income towards Parent Company figures came in at -$3.3 million (Q2 2025), -$46223.4 (Q3 2024), and -$4.6 million (Q2 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 211.73 Bn 197.74 Bn 7.24 Bn
2 Gilead Sciences 180.92 Bn 177.74 Bn 6.22 Bn
3 Vertex Pharmaceuticals 132.16 Bn 124.30 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 82.89 Bn 74.90 Bn 3.93 Bn
5 Argenx Se 61.41 Bn 56.23 Bn 1.37 Bn
6 Moderna 53.99 Bn 48.85 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 34.48 Bn 31.18 Bn 992.69 Mn
8 Biogen 31.15 Bn 29.86 Bn 1.96 Bn
9 Roivant Sciences 30.05 Bn 30.05 Bn 1.16 Mn
10 Immuron 10.28 Mn 1.26 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 -3.34 Mn
Sep 9, 2024 -46,223.37
Jun 30, 2024 -4.57 Mn
Dec 31, 2023 -24,649.80
Jun 30, 2023 -1.24 Mn
Dec 31, 2022 -352,470.52
Dec 31, 2021 -13,260.17
Jun 30, 2021 -6.46 Mn
Dec 31, 2020 -41,946.68
Jun 30, 2020 -1.92 Mn
Dec 31, 2019 -15,212.27
Dec 31, 2018 -1.58 Mn
Dec 31, 2017 3.79 Mn
Dec 31, 2016 2.57 Mn
Jun 30, 2016 -3.28 Mn